Patents by Inventor Amin Al-Shami

Amin Al-Shami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for use of TSLP and agonists and antagonists thereof
    Patent number: 7731953
    Abstract: Methods are disclosed herein for specifically inducing proliferation of CD4+ T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: June 8, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, Whitehead Institute of Biomedical Research
    Inventors: Warren J. Leonard, Akhilesh Pandey, Amin Al-Shami, Rosanne Spolski
  • METHODS FOR USE OF TSLP AND AGONISTS AND ANTAGONISTS THEREOF
    Publication number: 20070237787
    Abstract: Methods are disclosed herein for specifically inducing proliferation of CD4+ T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein.
    Type: Application
    Filed: June 13, 2007
    Publication date: October 11, 2007
    Applicants: GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY , DEPA, WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Warren Leonard, Akhilesh Pandey, Amin Al-Shami, Rosanne Spolski, John Kelly, Andrea Keane-Myers
  • Methods for use of TSLP and agonists and antagonists thereof
    Publication number: 20050249712
    Abstract: Methods are disclosed herein for specifically inducing proliferation of CD4+ T cells. The methods are of use in treating immunodeficiencies, such as an immunodeficiency produced by infection with an immunodeficiency virus, such as infection with a human immunodeficiency virus (HIV). The methods include contacting isolated mammalian CD4+ T cells with an effective amount of a thymic stromal derived lymphopoietin (TSLP) polypeptide or a therapeutically effective amount of nucleic acid encoding the TSLP polypeptide, thereby inducing proliferation of the T cells. Methods are also disclosed for treating an IgE mediated disorder, such as asthma. The methods include administering to a subject a therapeutically effective amount of a TSLP antagonist. Transgenic mice are also disclosed herein.
    Type: Application
    Filed: March 18, 2005
    Publication date: November 10, 2005
    Inventors: Warren Leonard, Akhilesh Pandey, Amin Al-Shami, Rosanne Spolski, John Kelly, Andrea Keane-Myers